Pasar al contenido principal

ENGRAMAS DE MEMORIA EN EL SINDROME DE DOWN: ALTERACIONES CELULARES Y MOLECULARES

PID2019-110755RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO CENTRE DE REGULACIO GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Fluorescent transgenic mouse models for whole-brain imaging in health and disease

  • Arias, Adrian
  • Manubens-Gil, Linus, 1989-
  • Dierssen, Mara
A paradigm shift is occurring in neuroscience and in general in life sciences converting biomedical research from a descriptive discipline into a quantitative, predictive, actionable science. Living systems are becoming amenable to quantitative description, with profound consequences for our ability to predict biological phenomena. New experimental tools such as tissue clearing, whole-brain imaging, and genetic engineering technologies have opened the opportunity to embrace this new paradigm, allowing to extract anatomical features such as cell number, their full morphology, and even their structural connectivity. These tools will also allow the exploration of new features such as their geometrical arrangement, within and across brain regions. This would be especially important to better characterize brain function and pathological alterations in neurological, neurodevelopmental, and neurodegenerative disorders. New animal models for mapping fluorescent protein-expressing neurons and axon pathways in adult mice are key to this aim. As a result of both developments, relevant cell populations with endogenous fluorescence signals can be comprehensively and quantitatively mapped to whole-brain images acquired at submicron resolution. However, they present intrinsic limitations: weak fluorescent signals, unequal signal strength across the same cell type, lack of specificity of fluorescent labels, overlapping signals in cell types with dense labeling, or undetectable signal at distal parts of the neurons, among others. In this review, we discuss the recent advances in the development of fluorescent transgenic mouse models that overcome to some extent the technical and conceptual limitations and tradeoffs between different strategies. We also discuss the potential use of these strains for understanding disease., The lab of MD was supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 848077. This reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (Grant Number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and JPND (Heroes AC170006). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome

  • Martínez de Lagrán Cabredo, María
  • Elizalde-Torrent, Aleix
  • Paredes, Roger
  • Clotet, Bonaventura
  • Dierssen, Mara
An elevated activity of retrotransposons is increasingly recognized to be implicated in a wide range of neurodegenerative and neurodevelopmental diseases. Down syndrome (DS) is the most common genetic disorder associated with intellectual disability and a genetic form of Alzheimer's disease. For this reason, we hypothesized that treatment with reverse transcriptase inhibitors could ameliorate DS phenotypes. In this proof of concept study, we treated trisomic (Ts65Dn) mice, a model of DS, with lamivudine, a reverse transcriptase inhibitor. We detected a significant improvement of neurobehavioural phenotypes, and a complete rescue of the hippocampal-dependent recognition memory upon treatment with lamivudine. Despite clinical studies in patients with DS are warranted, this study lays the groundwork for a novel and actionable therapeutic approach., Agencia Estatal de Investigación. Grant Number: PID2019-110755RB-I00/AEI/10.13039/501100011033. Horizon 2020 Framework Programme. Grant Number: 848077
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Proteomic profiling reveals mitochondrial dysfunction in the cerebellum of transgenic mice overexpressing DYRK1A, a Down syndrome candidate gene

  • Ortega, Mireia
  • De Toma, Ilario
  • Fernández-Blanco, Álvaro
  • Calderón Moruno, Anna
  • Barahona, Lucía
  • Trullàs, Ramón
  • Sabidó Aguadé, Eduard, 1981-
  • Dierssen, Mara
Introduction: DYRK1A is a dual-specificity kinase that is overexpressed in Down syndrome (DS) and plays a key role in neurogenesis, neuronal differentiation and function, cognitive phenotypes, and aging. Dyrk1A has also been implicated in cerebellar abnormalities observed in association with DS, and normalization of Dyrk1A dosage rescues granular and Purkinje cell densities in a trisomic DS mouse model. However, the underlying molecular mechanisms governing these processes are unknown. Methods: To shed light on the effects of Dyrk1A overexpression in the cerebellum, here we investigated the cerebellar proteome in transgenic Dyrk1A overexpressing mice in basal conditions and after treatment with green tea extract containing epigallocatechin-3-gallate (EGCG), a DYRK1A inhibitor. Results and discussion: Our results showed that Dyrk1A overexpression alters oxidative phosphorylation and mitochondrial function in the cerebellum of transgenic mice. These alterations are significantly rescued upon EGCG-containing green tea extract treatment, suggesting that its effects in DS could depend in part on targeting mitochondria, as shown by the partially restoration by the treatment of the increased mtDNA copy number in TG non-treated mice., This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Framework Programme under grant agreement no 848077. This reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (grant number 2002), NIH Blueprint for Neuroscience Research (grant number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and EU Joint Programme—Neurodegenerative Disease Research (Heroes AC170006). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Neurodevelopmental disorders: 2023 update

  • Carriba, Paulina
  • Lorenzon, Nicola
  • Dierssen, Mara
Several advances in the field of neurodevelopmental diseases (NDDs) have been reported by 2022. Of course, NDDs comprise a diverse group of disorders, most of which with different aetiologies. However, owing to the development and consolidation of technological approaches, such as proteomics and RNA-sequencing, and to the improvement of brain organoids along with the introduction of artificial intelligence (AI) for biodata analysis, in 2022 new aetiological mechanisms for some NDDs have been proposed. Here, we present hints of some of these findings. For instance, centrioles regulate neuronal migration and could be behind the aetiology of periventricular heterotopia; also, the accumulation of misfolded proteins could explain the neurological effects in COVID-19 patients; and, autism spectrum disorders (ASD) could be the expression of altered cortical arealization. We also cover other interesting aspects as the description of a new NDD characterized by deregulation of genes involved in stress granule (SG) assemblies, or the description of a newly discovered neural progenitor that explains the different phenotypes of tumours and cortical tubers in tuberous sclerosis complex (TSC) disease; and how it is possible to decipher the aetiology of sudden unexplained death in childhood (SUDC) or improve the diagnosis of cortical malformations using formalin-fixed paraffin-embedded samples., The lab of M.D. is supported by the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2022), the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 research and innovation programme under grant agreements nº 848077 (GO-DS21) and under grant agreement nº 899986 (ICOD). Horizon Europe (Horizon-Hlth-2021-StayHlth-01-Psych-STRATA). This reflects only the author's view, and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (Grant number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2022-12-30-31-32). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Beyond quiescent and active: Intermediate microglial transcriptomic states in a mouse model of down syndrome

  • Fernández Blanco, Álvaro
  • Sierra, Cesar
  • Tejido, Clara
  • Dierssen, Mara
Research on microglia in Down syndrome (DS) has shown that microglial activation, increased inflammatory gene expression, and oxidative stress occur at different ages in DS brains. However, most studies resulted in simplistic definitions of microglia as quiescent or active, ignoring potential intermediate states. Indeed, recent work on microglial cells in young DS brains indicated that those evolve through different intermediate activation phenotypes before reaching a fully activated state. Here we used single nucleus RNA sequencing, to examine how trisomy affects microglial states in the Ts65Dn mouse model of DS. Despite no substantial changes in the proportion of glial populations, differential expression analysis revealed cell type-specific gene expression changes, most notably in astroglia, microglia, and oligodendroglia. Focusing on microglia, we identified differential expression of genes associated with different microglial states, including disease-associated microglia (DAMs), activated response microglia (ARMs), and human Alzheimer's disease microglia (HAMs), in trisomic microglia. Furthermore, pseudotime analysis reveals a unique reactivity profile in Ts65Dn microglia, with fewer in a homeostatic state and more in an intermediate aberrantly reactive state than in euploid microglia. This comprehensive understanding of microglial transcriptional dynamics sheds light on potential pathogenetic mechanisms but also possible avenues for therapy for neurodevelopmental disorders., The lab of MD is recognized by the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). This project has received funding from the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033; PID2022-141900OB-I00 INTO-DS), from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848077 and 899986, Jerôme Lejeune Foundation #2002, Fundació La Marató-TV3 (#2016/20-30), JPND Heroes Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1; and CPP2022-009659). The CIBER of Rare Diseases is an initiative of the ISCIII. C.S. received the FI grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya, and A.F.B. received an FPI-SO fellowship (PRE2018-084504).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A novel way to use cross-validation to measure connectivity by machine learning allows epilepsy surgery outcome prediction

  • Ivankovic, Karla
  • Principe, Alessandro
  • Montoya Gálvez, Justo
  • Manubens-Gil, Linus, 1989-
  • Zucca, Riccardo
  • Villoslada, Pablo
  • Dierssen, Mara
  • Rocamora Zúñiga, Rodrigo Alberto
The rate of success of epilepsy surgery, ensuring seizure-freedom, is limited by the lack of epileptogenicity biomarkers. Previous evidence supports the critical role of functional connectivity during seizure generation to characterize the epileptogenic network (EN). However, EN dynamics is highly variable across patients, hindering the development of diagnostic biomarkers. Without relying on specific connectivity variables, we focused on a general hypothesis that the EN undergoes the greatest magnitude of connectivity change during seizure generation, compared to other brain networks. To test this hypothesis, we developed a novel method for quantifying connectivity change between network states and applied it to identify surgical resection areas. A network state was represented by random snapshots of connectivity within a defined time interval of an intracranial EEG recording. A binary classifier was applied to classify two network states. The classifier generalization performance estimated by cross-validation was employed as a continuous measure of connectivity change. The algorithm generated a network by iteratively adding nodes until the connectivity change magnitude decreased. The resulting network was compared to the surgical resection, and the overlap score was used to predict post-surgical outcomes. The framework was evaluated in a consecutive cohort of 21 patients with a post-surgical follow-up of minimum 3 years. The best overlap between connectivity change networks and resections was obtained at the transition from pre-seizure to seizure (surgical outcome prediction ROC-AUC=90.3 %). However, all patients except one were correctly classified when considering the most informative time intervals. Time intervals proportional to seizure length were more informative than the almost universally used fixed intervals. This study demonstrates that connectivity can be successfully classified with a machine learning analysis and provide information for distinguishing a separate epileptogenic functional network. In summary, the connectivity change analysis could accurately identify epileptogenic networks validated by surgery outcome classification. Connectivity change magnitude at seizure transition could potentially serve as an EN biomarker. The tool provided by this study may aid surgical decision-making., FLAG–ERA JTC 2017 Human Brain Project, CAUSALTOMICS (PCI2018–092860) (AP, KI). Fundación Tatiana - Proyectos en Neurociencia - Grant 2022–1514 (AP). Ajuts destinats a universitats, centres de recerca i fundacions hospitalàries per contractar personal investigador novell per a l'any 2022 (FI-DGR Grant Number: 14802) (KI). Emergent Cluster of the Human Brain (CECH) and the European Regional Development Fund (FEDER) 001-P-001682 (RZ). The lab of MD was supported by the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). Agencia Estatal de Investigación (PID2019–110755RB-I00/AEI/10.13039/501100011033) (MD). The European Union's Horizon 2020 Research and Innovation Program under grant agreement No 848077 (MD). NIH (Grant Number: 1R01EB 028159–01) (MD). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A dynamic in vitro model of Down syndrome neurogenesis with trisomy 21 gene dosage correction

  • Bansal, Prakhar
  • Banda, Erin C.
  • Glatt-Deeley, Heather R.
  • Stoddard, Christopher E.
  • Linsley, Jeremy W.
  • Arora, Neha
  • Deleschaux, Cécile
  • Ahern, Darcy T.
  • Kondaveeti, Yuvabharath
  • Massey, Rachael E.
  • Nicouleau, Michael
  • Wang, Shijie
  • Sabariego Navarro, Miguel
  • Dierssen, Mara
  • Finkbeiner, Steven
  • Pinter, Stefan F.
Excess gene dosage from chromosome 21 (chr21) causes Down syndrome (DS), spanning developmental and acute phenotypes in terminal cell types. Which phenotypes remain amenable to intervention after development is unknown. To address this question in a model of DS neurogenesis, we derived trisomy 21 (T21) human induced pluripotent stem cells (iPSCs) alongside, otherwise, isogenic euploid controls from mosaic DS fibroblasts and equipped one chr21 copy with an inducible XIST transgene. Monoallelic chr21 silencing by XIST is near-complete and irreversible in iPSCs. Differential expression reveals that T21 neural lineages and iPSCs share suppressed translation and mitochondrial pathways and activate cellular stress responses. When XIST is induced before the neural progenitor stage, T21 dosage correction suppresses a pronounced skew toward astrogenesis in neural differentiation. Because our transgene remains inducible in postmitotic T21 neurons and astrocytes, we demonstrate that XIST efficiently represses genes even after terminal differentiation, which will empower exploration of cell type-specific T21 phenotypes that remain responsive to chr21 dosage., This work was supported by grants from the LuMind IDSC Foundation and the NIH (R35GM124926, with additional support from R01HL141324) to S.F.P. Support for work conducted at the Gladstone Institutes (to S.F.) came from R01 AG064579 with additional support from R01 LM013617, RF1 NS128800, and the JSRM Foundation. Work at the Centre for Genomic Regulation (to M.D.) was supported by the Fondation Jérôme Lejeune #2002, Fundació La Marató De TV 3 202212-30-31-32, and Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya, and FPU fellowship (FPU19/04789) from Ministerio de Universidades (to M.S.-N.) The CIBER of Rare Diseases is an initiative of the ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proteomic profiling reveals mitochondrial dysfunction in the cerebellum of transgenic mice overexpressing DYRK1A, a Down syndrome candidate gene

  • Ortega, Mireia
  • Toma, Ilario de
  • Fernández-Blanco, Álvaro
  • Calderón, Anna
  • Barahona, Lucía
  • Trullas, Ramón
  • Sabidó, Eduard
  • Dierssen, Mara
Introduction: DYRK1A is a dual-specificity kinase that is overexpressed in Down syndrome (DS) and plays a key role in neurogenesis, neuronal differentiation and function, cognitive phenotypes, and aging. Dyrk1A has also been implicated in cerebellar abnormalities observed in association with DS, and normalization of Dyrk1A dosage rescues granular and Purkinje cell densities in a trisomic DS mouse model. However, the underlying molecular mechanisms governing these processes are unknown. Methods: To shed light on the effects of Dyrk1A overexpression in the cerebellum, here we investigated the cerebellar proteome in transgenic Dyrk1A overexpressing mice in basal conditions and after treatment with green tea extract containing epigallocatechin-3-gallate (EGCG), a DYRK1A inhibitor. Results and Discussion: Our results showed that Dyrk1A overexpression alters oxidative phosphorylation and mitochondrial function in the cerebellum of transgenic mice. These alterations are significantly rescued upon EGCG-containing green tea extract treatment, suggesting that its effects in DS could depend in part on targeting mitochondria, as shown by the partially restoration by the treatment of the increased mtDNA copy number in TG non-treated mice., This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Framework Programme under grant agreement no 848077. This reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (grant number 2002), NIH Blueprint for Neuroscience Research (grant number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and EU Joint Programme—Neurodegenerative Disease Research (Heroes AC170006). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A

  • Manubens-Gil, Linus
  • Pons-Espinal, Meritxell
  • Gener, Thomas
  • Ballesteros-Yañez, Inmaculada
  • Martínez de Lagrán, María
  • Dierssen, Mara
In this study, we investigated the impact of Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) overexpression, a gene associated with Down syndrome, on hippocampal neuronal deficits in mice. Our findings revealed that mice overexpressing Dyrk1A (TgDyrk1A; TG) exhibited impaired hippocampal recognition memory, disrupted excitation-inhibition balance, and deficits in long-term potentiation (LTP). Specifically, we observed layer-specific deficits in dendritic arborization of TG CA1 pyramidal neurons in the stratum radiatum. Through computational modeling, we determined that these alterations resulted in reduced storage capacity and compromised integration of inputs, with decreased high γ oscillations. Contrary to prevailing assumptions, our model suggests that deficits in neuronal architecture, rather than over-inhibition, primarily contribute to the reduced network. We explored the potential of environmental enrichment (EE) as a therapeutic intervention and found that it normalized the excitation-inhibition balance, restored LTP, and improved short-term recognition memory. Interestingly, we observed transient significant dendritic remodeling, leading to recovered high γ. However, these effects were not sustained after EE discontinuation. Based on our findings, we conclude that Dyrk1A overexpression-induced layer-specific neuromorphological disturbances impair the encoding of place and temporal context. These findings contribute to our understanding of the underlying mechanisms of Dyrk1A-related hippocampal deficits and highlight the challenges associated with long-term therapeutic interventions for cognitive impairments., We acknowledge support of the Spanish Ministry of Economy and Competitiveness (MINECO), “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208. The research leading to these results has received funding from MINECO (SAF2013-49129-C2-1-R; PID2022-141900OB-I00 and PID2019-110755RB-I00/AEI/10.13039/501100011033), H2020 SC1 Gene overdosage and comorbidities during the early lifetime in DS GO-DS21-848077, Jerôme Lejeune Foundation #2002, the NIH grant R01 EB028159 We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa ((CEX2020-001049-S, MCIN/AEI/10.13039/501100011033)) and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases is an initiative of the ISCIII., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001049-S), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome

  • Martínez de Lagrán Cabredo, María
  • Elizalde-Torrent, Aleix
  • Paredes, Roger
  • Clotet, Bonaventura
  • Dierssen, Mara
An elevated activity of retrotransposons is increasingly recognized to be implicated in a wide range of neurodegenerative and neurodevelopmental diseases. Down syndrome (DS) is the most common genetic disorder associated with intellectual disability and a genetic form of Alzheimer's disease. For this reason, we hypothesized that treatment with reverse transcriptase inhibitors could ameliorate DS phenotypes. In this proof of concept study, we treated trisomic (Ts65Dn) mice, a model of DS, with lamivudine, a reverse transcriptase inhibitor. We detected a significant improvement of neurobehavioural phenotypes, and a complete rescue of the hippocampal-dependent recognition memory upon treatment with lamivudine. Despite clinical studies in patients with DS are warranted, this study lays the groundwork for a novel and actionable therapeutic approach., Agencia Estatal de Investigación. Grant Number: PID2019-110755RB-I00/AEI/10.13039/501100011033. Horizon 2020 Framework Programme. Grant Number: 848077
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neurodevelopmental disorders: 2023 update

  • Carriba, Paulina
  • Lorenzon, Nicola
  • Dierssen, Mara
Several advances in the field of neurodevelopmental diseases (NDDs) have been reported by 2022. Of course, NDDs comprise a diverse group of disorders, most of which with different aetiologies. However, owing to the development and consolidation of technological approaches, such as proteomics and RNA-sequencing, and to the improvement of brain organoids along with the introduction of artificial intelligence (AI) for biodata analysis, in 2022 new aetiological mechanisms for some NDDs have been proposed. Here, we present hints of some of these findings. For instance, centrioles regulate neuronal migration and could be behind the aetiology of periventricular heterotopia; also, the accumulation of misfolded proteins could explain the neurological effects in COVID-19 patients; and, autism spectrum disorders (ASD) could be the expression of altered cortical arealization. We also cover other interesting aspects as the description of a new NDD characterized by deregulation of genes involved in stress granule (SG) assemblies, or the description of a newly discovered neural progenitor that explains the different phenotypes of tumours and cortical tubers in tuberous sclerosis complex (TSC) disease; and how it is possible to decipher the aetiology of sudden unexplained death in childhood (SUDC) or improve the diagnosis of cortical malformations using formalin-fixed paraffin-embedded samples., The lab of M.D. is supported by the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2022), the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 research and innovation programme under grant agreements nº 848077 (GO-DS21) and under grant agreement nº 899986 (ICOD). Horizon Europe (Horizon-Hlth-2021-StayHlth-01-Psych-STRATA). This reflects only the author's view, and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (Grant number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2022-12-30-31-32). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A novel way to use cross-validation to measure connectivity by machine learning allows epilepsy surgery outcome prediction

  • Ivankovic, Karla
  • Principe, Alessandro
  • Montoya Gálvez, Justo
  • Manubens-Gil, Linus, 1989-
  • Zucca, Riccardo
  • Villoslada, Pablo
  • Dierssen, Mara
  • Rocamora Zúñiga, Rodrigo Alberto
The rate of success of epilepsy surgery, ensuring seizure-freedom, is limited by the lack of epileptogenicity biomarkers. Previous evidence supports the critical role of functional connectivity during seizure generation to characterize the epileptogenic network (EN). However, EN dynamics is highly variable across patients, hindering the development of diagnostic biomarkers. Without relying on specific connectivity variables, we focused on a general hypothesis that the EN undergoes the greatest magnitude of connectivity change during seizure generation, compared to other brain networks. To test this hypothesis, we developed a novel method for quantifying connectivity change between network states and applied it to identify surgical resection areas. A network state was represented by random snapshots of connectivity within a defined time interval of an intracranial EEG recording. A binary classifier was applied to classify two network states. The classifier generalization performance estimated by cross-validation was employed as a continuous measure of connectivity change. The algorithm generated a network by iteratively adding nodes until the connectivity change magnitude decreased. The resulting network was compared to the surgical resection, and the overlap score was used to predict post-surgical outcomes. The framework was evaluated in a consecutive cohort of 21 patients with a post-surgical follow-up of minimum 3 years. The best overlap between connectivity change networks and resections was obtained at the transition from pre-seizure to seizure (surgical outcome prediction ROC-AUC=90.3 %). However, all patients except one were correctly classified when considering the most informative time intervals. Time intervals proportional to seizure length were more informative than the almost universally used fixed intervals. This study demonstrates that connectivity can be successfully classified with a machine learning analysis and provide information for distinguishing a separate epileptogenic functional network. In summary, the connectivity change analysis could accurately identify epileptogenic networks validated by surgery outcome classification. Connectivity change magnitude at seizure transition could potentially serve as an EN biomarker. The tool provided by this study may aid surgical decision-making., FLAG–ERA JTC 2017 Human Brain Project, CAUSALTOMICS (PCI2018–092860) (AP, KI). Fundación Tatiana - Proyectos en Neurociencia - Grant 2022–1514 (AP). Ajuts destinats a universitats, centres de recerca i fundacions hospitalàries per contractar personal investigador novell per a l'any 2022 (FI-DGR Grant Number: 14802) (KI). Emergent Cluster of the Human Brain (CECH) and the European Regional Development Fund (FEDER) 001-P-001682 (RZ). The lab of MD was supported by the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). Agencia Estatal de Investigación (PID2019–110755RB-I00/AEI/10.13039/501100011033) (MD). The European Union's Horizon 2020 Research and Innovation Program under grant agreement No 848077 (MD). NIH (Grant Number: 1R01EB 028159–01) (MD). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteomic profiling reveals mitochondrial dysfunction in the cerebellum of transgenic mice overexpressing DYRK1A, a Down syndrome candidate gene

  • Ortega, Mireia
  • De Toma, Ilario
  • Fernández-Blanco, Álvaro
  • Calderón Moruno, Anna
  • Barahona, Lucía
  • Trullàs, Ramón
  • Sabidó Aguadé, Eduard, 1981-
  • Dierssen, Mara
Introduction: DYRK1A is a dual-specificity kinase that is overexpressed in Down syndrome (DS) and plays a key role in neurogenesis, neuronal differentiation and function, cognitive phenotypes, and aging. Dyrk1A has also been implicated in cerebellar abnormalities observed in association with DS, and normalization of Dyrk1A dosage rescues granular and Purkinje cell densities in a trisomic DS mouse model. However, the underlying molecular mechanisms governing these processes are unknown. Methods: To shed light on the effects of Dyrk1A overexpression in the cerebellum, here we investigated the cerebellar proteome in transgenic Dyrk1A overexpressing mice in basal conditions and after treatment with green tea extract containing epigallocatechin-3-gallate (EGCG), a DYRK1A inhibitor. Results and discussion: Our results showed that Dyrk1A overexpression alters oxidative phosphorylation and mitochondrial function in the cerebellum of transgenic mice. These alterations are significantly rescued upon EGCG-containing green tea extract treatment, suggesting that its effects in DS could depend in part on targeting mitochondria, as shown by the partially restoration by the treatment of the increased mtDNA copy number in TG non-treated mice., This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Framework Programme under grant agreement no 848077. This reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (grant number 2002), NIH Blueprint for Neuroscience Research (grant number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and EU Joint Programme—Neurodegenerative Disease Research (Heroes AC170006). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Fluorescent transgenic mouse models for whole-brain imaging in health and disease

  • Arias, Adrian
  • Manubens-Gil, Linus, 1989-
  • Dierssen, Mara
A paradigm shift is occurring in neuroscience and in general in life sciences converting biomedical research from a descriptive discipline into a quantitative, predictive, actionable science. Living systems are becoming amenable to quantitative description, with profound consequences for our ability to predict biological phenomena. New experimental tools such as tissue clearing, whole-brain imaging, and genetic engineering technologies have opened the opportunity to embrace this new paradigm, allowing to extract anatomical features such as cell number, their full morphology, and even their structural connectivity. These tools will also allow the exploration of new features such as their geometrical arrangement, within and across brain regions. This would be especially important to better characterize brain function and pathological alterations in neurological, neurodevelopmental, and neurodegenerative disorders. New animal models for mapping fluorescent protein-expressing neurons and axon pathways in adult mice are key to this aim. As a result of both developments, relevant cell populations with endogenous fluorescence signals can be comprehensively and quantitatively mapped to whole-brain images acquired at submicron resolution. However, they present intrinsic limitations: weak fluorescent signals, unequal signal strength across the same cell type, lack of specificity of fluorescent labels, overlapping signals in cell types with dense labeling, or undetectable signal at distal parts of the neurons, among others. In this review, we discuss the recent advances in the development of fluorescent transgenic mouse models that overcome to some extent the technical and conceptual limitations and tradeoffs between different strategies. We also discuss the potential use of these strains for understanding disease., The lab of MD was supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 848077. This reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (Grant Number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and JPND (Heroes AC170006). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A dynamic in vitro model of Down syndrome neurogenesis with trisomy 21 gene dosage correction

  • Bansal, Prakhar
  • Banda, Erin C.
  • Glatt-Deeley, Heather R.
  • Stoddard, Christopher E.
  • Linsley, Jeremy W.
  • Arora, Neha
  • Deleschaux, Cécile
  • Ahern, Darcy T.
  • Kondaveeti, Yuvabharath
  • Massey, Rachael E.
  • Nicouleau, Michael
  • Wang, Shijie
  • Sabariego Navarro, Miguel
  • Dierssen, Mara
  • Finkbeiner, Steven
  • Pinter, Stefan F.
Excess gene dosage from chromosome 21 (chr21) causes Down syndrome (DS), spanning developmental and acute phenotypes in terminal cell types. Which phenotypes remain amenable to intervention after development is unknown. To address this question in a model of DS neurogenesis, we derived trisomy 21 (T21) human induced pluripotent stem cells (iPSCs) alongside, otherwise, isogenic euploid controls from mosaic DS fibroblasts and equipped one chr21 copy with an inducible XIST transgene. Monoallelic chr21 silencing by XIST is near-complete and irreversible in iPSCs. Differential expression reveals that T21 neural lineages and iPSCs share suppressed translation and mitochondrial pathways and activate cellular stress responses. When XIST is induced before the neural progenitor stage, T21 dosage correction suppresses a pronounced skew toward astrogenesis in neural differentiation. Because our transgene remains inducible in postmitotic T21 neurons and astrocytes, we demonstrate that XIST efficiently represses genes even after terminal differentiation, which will empower exploration of cell type-specific T21 phenotypes that remain responsive to chr21 dosage., This work was supported by grants from the LuMind IDSC Foundation and the NIH (R35GM124926, with additional support from R01HL141324) to S.F.P. Support for work conducted at the Gladstone Institutes (to S.F.) came from R01 AG064579 with additional support from R01 LM013617, RF1 NS128800, and the JSRM Foundation. Work at the Centre for Genomic Regulation (to M.D.) was supported by the Fondation Jérôme Lejeune #2002, Fundació La Marató De TV 3 202212-30-31-32, and Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya, and FPU fellowship (FPU19/04789) from Ministerio de Universidades (to M.S.-N.) The CIBER of Rare Diseases is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Beyond quiescent and active: Intermediate microglial transcriptomic states in a mouse model of down syndrome

  • Fernández Blanco, Álvaro
  • Sierra, Cesar
  • Tejido, Clara
  • Dierssen, Mara
Research on microglia in Down syndrome (DS) has shown that microglial activation, increased inflammatory gene expression, and oxidative stress occur at different ages in DS brains. However, most studies resulted in simplistic definitions of microglia as quiescent or active, ignoring potential intermediate states. Indeed, recent work on microglial cells in young DS brains indicated that those evolve through different intermediate activation phenotypes before reaching a fully activated state. Here we used single nucleus RNA sequencing, to examine how trisomy affects microglial states in the Ts65Dn mouse model of DS. Despite no substantial changes in the proportion of glial populations, differential expression analysis revealed cell type-specific gene expression changes, most notably in astroglia, microglia, and oligodendroglia. Focusing on microglia, we identified differential expression of genes associated with different microglial states, including disease-associated microglia (DAMs), activated response microglia (ARMs), and human Alzheimer's disease microglia (HAMs), in trisomic microglia. Furthermore, pseudotime analysis reveals a unique reactivity profile in Ts65Dn microglia, with fewer in a homeostatic state and more in an intermediate aberrantly reactive state than in euploid microglia. This comprehensive understanding of microglial transcriptional dynamics sheds light on potential pathogenetic mechanisms but also possible avenues for therapy for neurodevelopmental disorders., The lab of MD is recognized by the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). This project has received funding from the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033; PID2022-141900OB-I00 INTO-DS), from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848077 and 899986, Jerôme Lejeune Foundation #2002, Fundació La Marató-TV3 (#2016/20-30), JPND Heroes Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1; and CPP2022-009659). The CIBER of Rare Diseases is an initiative of the ISCIII. C.S. received the FI grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya, and A.F.B. received an FPI-SO fellowship (PRE2018-084504).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of covid-19 and non-covid-19 pneumonia in down syndrome

  • Real de Asua, Diego
  • Mayer, Miguel Angel|||0000-0003-0362-6298
  • Del Carmen Ortega, María
  • Borrel, Jose M.
  • de Jesús Bermejo, Teresa
  • González-lamuño, Domingo|||0000-0002-7578-241X
  • Manso, Coral
  • Moldenhauer, Fernando|||0000-0002-6259-8226
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Hüls, Anke|||0000-0002-6005-417X
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Dierssen, Mara|||0000-0003-0853-6865
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID- 19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A

  • Manubens-Gil, Linus|||0000-0003-2036-2204
  • Pons-Espinal, Meritxell|||0000-0003-0832-2963
  • Gener, Thomas|||0000-0001-9209-9228
  • Ballesteros-Yañez, Inmaculada|||0000-0003-4362-027X
  • Martínez de Lagrán, María|||0000-0002-0836-6491
  • Dierssen, Mara|||0000-0003-0853-6865
In this study, we investigated the impact of Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) overexpression, a gene associated with Down syndrome, on hippocampal neuronal deficits in mice. Our findings revealed that mice overexpressing Dyrk1A (TgDyrk1A; TG) exhibited impaired hippocampal recognition memory, disrupted excitation-inhibition balance, and deficits in long-term potentiation (LTP). Specifically, we observed layer-specific deficits in dendritic arborization of TG CA1 pyramidal neurons in the stratum radiatum. Through computational modeling, we determined that these alterations resulted in reduced storage capacity and compromised integration of inputs, with decreased high γ oscillations. Contrary to prevailing assumptions, our model suggests that deficits in neuronal architecture, rather than over-inhibition, primarily contribute to the reduced network. We explored the potential of environmental enrichment (EE) as a therapeutic intervention and found that it normalized the excitation-inhibition balance, restored LTP, and improved short-term recognition memory. Interestingly, we observed transient significant dendritic remodeling, leading to recovered high γ. However, these effects were not sustained after EE discontinuation. Based on our findings, we conclude that Dyrk1A overexpression-induced layer-specific neuromorphological disturbances impair the encoding of place and temporal context. These findings contribute to our understanding of the underlying mechanisms of Dyrk1A-related hippocampal deficits and highlight the challenges associated with long-term therapeutic interventions for cognitive impairments.